68 related articles for article (PubMed ID: 25608826)
1. Thrombocytopenia due to low-dose colchicine therapy: A possible drug interaction with nivolumab and implications for supportive care.
Solomon LR
Acta Oncol; 2015; 54(8):1235-7. PubMed ID: 25608826
[No Abstract] [Full Text] [Related]
2. Colchicine: the good, the bad, the ugly and how to minimize the risks.
Stamp LK; Horsley C; Te Karu L; Dalbeth N; Barclay M
Rheumatology (Oxford); 2024 Apr; 63(4):936-944. PubMed ID: 38019947
[TBL] [Abstract][Full Text] [Related]
3. Colchicine Drug Interaction Errors and Misunderstandings: Recommendations for Improved Evidence-Based Management.
Hansten PD; Tan MS; Horn JR; Gomez-Lumbreras A; Villa-Zapata L; Boyce RD; Subbian V; Romero A; Gephart S; Malone DC
Drug Saf; 2023 Mar; 46(3):223-242. PubMed ID: 36522578
[TBL] [Abstract][Full Text] [Related]
4. A case report of colchicine toxicity progressing from diarrhea to rhabdomyolysis: The probable role of interaction with ciprofloxacin.
Murt A
Int J Rheum Dis; 2024 Jan; 27(1):e15019. PubMed ID: 38186014
[No Abstract] [Full Text] [Related]
5. Therapeutic drugs of gout: The progress in target selection.
Lin P; Chen Z; Lin J
Int J Rheum Dis; 2024 Jan; 27(1):e15022. PubMed ID: 38152972
[No Abstract] [Full Text] [Related]
6. CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations.
Camacho LH
Cancer Med; 2015 May; 4(5):661-72. PubMed ID: 25619164
[TBL] [Abstract][Full Text] [Related]
7. The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Shin DS; Ribas A
Curr Opin Immunol; 2015 Apr; 33():23-35. PubMed ID: 25621841
[TBL] [Abstract][Full Text] [Related]
8. Nivolumab provides favorable results in patients with advanced melanoma.
Dangi-Garimella S
Am J Manag Care; 2014 Mar; 20(5 Spec No.):E11. PubMed ID: 25618626
[No Abstract] [Full Text] [Related]
9. PD-1 and PD-L1 antibodies for melanoma.
Tsai KK; Zarzoso I; Daud AI
Hum Vaccin Immunother; 2014; 10(11):3111-6. PubMed ID: 25625924
[TBL] [Abstract][Full Text] [Related]
10. Ipilimumab-induced autoimmune hypophysitis: a differential for sellar mass lesions.
Rodrigues BT; Otty Z; Sangla K; Shenoy VV
Endocrinol Diabetes Metab Case Rep; 2014; 2014():140098. PubMed ID: 25614822
[TBL] [Abstract][Full Text] [Related]
11. Case of respiratory discomfort due to myositis after administration of nivolumab.
Yoshioka M; Kambe N; Yamamoto Y; Suehiro K; Matsue H
J Dermatol; 2015 Oct; 42(10):1008-9. PubMed ID: 26104017
[No Abstract] [Full Text] [Related]
12. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
Rizvi NA; Mazières J; Planchard D; Stinchcombe TE; Dy GK; Antonia SJ; Horn L; Lena H; Minenza E; Mennecier B; Otterson GA; Campos LT; Gandara DR; Levy BP; Nair SG; Zalcman G; Wolf J; Souquet PJ; Baldini E; Cappuzzo F; Chouaid C; Dowlati A; Sanborn R; Lopez-Chavez A; Grohe C; Huber RM; Harbison CT; Baudelet C; Lestini BJ; Ramalingam SS
Lancet Oncol; 2015 Mar; 16(3):257-65. PubMed ID: 25704439
[TBL] [Abstract][Full Text] [Related]
13. Nivolumab for advanced squamous cell lung cancer: what are the next steps?
de Mello RA; Pousa I; Pereira D
Lancet Oncol; 2015 Mar; 16(3):234-5. PubMed ID: 25704436
[No Abstract] [Full Text] [Related]
14. CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic.
Callahan MK; Postow MA; Wolchok JD
Front Oncol; 2014; 4():385. PubMed ID: 25642417
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab success in untreated metastatic melanoma.
Wilkinson E
Lancet Oncol; 2015 Jan; 16(1):e9. PubMed ID: 25638562
[No Abstract] [Full Text] [Related]
16. Bi-cytopenia possibly induced by anti-PD-1 antibody for primary malignant melanoma of the esophagus: A case report.
Inadomi K; Kumagai H; Arita S; Tsuruta N; Takayoshi K; Mishima K; Ota SI; Tanaka M; Okumura Y; Sagara K; Nio K; Nakano M; Uchi H; Yamamoto H; Ariyama H; Kusaba H; Niiro H; Oda Y; Akashi K; Baba E
Medicine (Baltimore); 2016 Jul; 95(29):e4283. PubMed ID: 27442668
[TBL] [Abstract][Full Text] [Related]
17. Partial Remission of Hepatic Metastatic Lesion but Complicated with Secondary and Refractory Fever Lead by Nivolumab in a Patient with Lung Adenocarcinoma Presenting Gefitinib Acquired Resistance.
Lian ZZ; Sun YF; Chen C
Chin Med J (Engl); 2016 Apr; 129(7):879-80. PubMed ID: 26996489
[No Abstract] [Full Text] [Related]
18. Severe rash associated with vemurafenib administration following nivolumab therapy.
Imafuku K; Yoshino K; Ishiwata K; Otobe S; Tsuboi S; Ohara K; Hata H
J Eur Acad Dermatol Venereol; 2016 Oct; 30(10):e84-e86. PubMed ID: 26372833
[No Abstract] [Full Text] [Related]
19. Occurrence of Psoriasiform Eruption During Nivolumab Therapy for Primary Oral Mucosal Melanoma.
Ohtsuka M; Miura T; Mori T; Ishikawa M; Yamamoto T
JAMA Dermatol; 2015 Jul; 151(7):797-9. PubMed ID: 25875052
[No Abstract] [Full Text] [Related]
20. Anticytotoxic T-lymphocyte antigen-4 induced autoimmune hypophysitis: a case report and literature review.
Majchel D; Korytkowski MT
Case Rep Endocrinol; 2015; 2015():570293. PubMed ID: 25694832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
